Positive CHMP recommendation for Sanofi’s atherosclerotic CVD drug Praluent

pharmafile | February 4, 2019 | News story | Sales and Marketing Europe, atherosclerotic cardiovascular disease, cvd, pharma, praluent 

It has been announced that Sanofi’s Praluent (alirocumab) has been awarded a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) as a treatment to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease (ASCVD).

ASCVD refers to a number of conditions characterised by a build-up of plaque in the body’s arteries, with the resulting reduced blood flow increasing the risk of stroke, peripheral artery disease and acute coronary syndrome (ACS), which includes heart attack and unstable angina.

The CHMP’s decision recommended that the therapy be used as an adjunct to a maximally tolerated statin dose, or as a monotherapy in patients for whom statins are an inappropriate or ineffective approach. Phase 3 data on the therapy’s efficacy in 18,924 participants was submitted in support of its application.

The ruling bodes well for Sanofi, with the FDA historically tending to frequently follow the advice of the advisory panel. The French manufacturer expects a final decision from the European Commission in the coming months. The FDA has also accepted the drug for review, with a prospective decision date set for 28 April this year.

Advertisement

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

stethoscope_and_background_doctor

Study finds new test could better predict risk of heart disease

A study by Harvard University, US, and Chalmers University of Technology, Sweden, has found that …

blood_test

Johnson & Johnson announces successful results from trial for myeloma treatment

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

The Gateway to Local Adoption Series

Latest content